January 7, 2021

 

VIA FACSIMILE AND EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, D.C.  20549

 

 

Re:

 Lexaria Bioscience Corp.

 

 Registration Statement on Form S-1 (Registration No. 333-250326)

 

 Concurrence in Acceleration Request

  

Ladies and Gentlemen:

 

H.C. Wainwright & Co., LLC (“Wainwright”), as managing underwriter for the above-referenced offering, hereby concurs in the request by Lexaria Bioscience Corp. that the effective date of the above-referenced registration statement be accelerated to 4:00 P.M. Eastern Time on Monday, January 11, 2021, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

  

 

Very truly yours,

 

 

 

 

 

H.C. WAINWRIGHT & CO., LLC

 

 

 

 

 

 

By:

/s/ Edward S. Silvera

 

 

Name:

Edward D. Silvera

 

 

Title:

Chief Operating Officer

 

 

 

 

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC